Long-term low-dose glucocorticoid therapy in hyperandrogenized women: utility and effects on bone mineral content and hypothalamic-pituitary-adrenocortical function

Horm Res. 1991;35(3-4):142-5. doi: 10.1159/000181890.

Abstract

The effect of chronic low-dose glucocorticoid administration on bone mineral content and corticotrope reserve was investigated in 12 hyperandrogenized women treated with 1-6 mg oral evening doses of 16 beta-methylprednisone for 12-58 months. The hypothalamic-pituitary-adrenal axis was evaluated in 9 patients by a standard metyrapone test after 45-75 days off steroid therapy. All the patients had a normal rise in serum 11-deoxycortisol after metyrapone. Bone densitometry was assessed at the end of therapy using dual photon absorptiometry. No significant differences between patients and age-matched hyperandrogenic controls were found either in spine (1.048 +/- 0.096 vs. 1.023 +/- 0.175 g/cm2) or femoral neck (0.863 +/- 0.115 vs. 0.899 +/- 0.216 g/cm2), respectively. In conclusion, absence of quantitative bone mass reduction and normal corticotrope reserve were observed even after 58 months of daily steroid administration.

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Adolescent
  • Adult
  • Bone Density / drug effects*
  • Cortodoxone / blood
  • Dehydroepiandrosterone / analogs & derivatives
  • Dehydroepiandrosterone / blood
  • Dehydroepiandrosterone Sulfate
  • Humans
  • Hypothalamo-Hypophyseal System / drug effects*
  • Metyrapone
  • Middle Aged
  • Pituitary-Adrenal System / drug effects*
  • Prednisone / analogs & derivatives*
  • Prednisone / therapeutic use
  • Testosterone / blood
  • Time Factors
  • Virilism / blood
  • Virilism / drug therapy*
  • Virilism / physiopathology

Substances

  • Testosterone
  • Dehydroepiandrosterone
  • Dehydroepiandrosterone Sulfate
  • meprednisone
  • Prednisone
  • Cortodoxone
  • Metyrapone